RAS Peptide Profiles in Patients With Treatment-resistant Arterial Hypertension

Completed

• Conditions: Hypertension

• Registration Number: NCT02962778
• Lead Sponsor: University Hospital, Basel, Switzerland

Brief Summary

This study evaluates RAS peptides profiles in patients with treatment resistant arterial hypertension.

Detailed Description

Selective quantification of RAS peptides in human plasma triggered investigations evaluating whether RAS peptides could be used as clinical biomarkers in patients receiving antihypertensive treatment.

Drug-specific RAS profiles first characterized in healthy normotensive subjects (EKBB 255/12; ClinicalTrials.gov ID NCT01771783) are presently investigated in patients with newly diagnosed arterial hypertension (EKNZ 2015-081; clinicaltrials.gov identifier (ID) NCT02449811). With this observational study RAS peptide profiles will be characterized in patients with treatment resistant hypertension. Data generated by this study will show whether RAS peptide profiles merit further evaluation as clinical biomarkers in this complex patient group.

Study Timeline

• Study Start: 2016-10
• Study First Submitted: 2016-11-09
• Study First Submitted QC: 2016-11-10
• Study First Posted: 2016-11-11
• Primary Completion: 2017-10
• Study Completion: 2017-10-11
• Status Verified: 2018-02
• Last Update Submitted: 2018-02-26
• Last Update Posted: 2018-02-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
RAS peptide concentrations in plasma	baseline, 4h after observed drug intake and steady-state sample

Secondary Outcome Measures

Name	Time	Method
Antihypertensive drug concentrations in plasma	baseline, 4h after observed drug intake and steady-state sample

Trial Locations

Locations (1)

University Hospital Basel; 🇨🇭 Basel, Switzerland